Pathology: mNSCLC - L1 - PDL1 positive; non squamous - mNSCLC - L1 - all population; non squamous - mNSCLC - L1 - Wild Type (WT); squamous - mNSCLC - L1 - all population;
| mNSCLC - L1 - PDL1 positive | non squamous - mNSCLC - L1 - all population | non squamous - mNSCLC - L1 - Wild Type (WT) | squamous - mNSCLC - L1 - all population | ||||||||||
| IMpower-110 (TC1/2/3 or IC1/2/3), 2020 | IMpower-110 (TC3 or IC3), 2020 | IMpower-110 (TC2/3 or IC2/3), 2020 | IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 | IMpower-130 (all population), 2019 | IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 | IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 | IMpower-150 (ABCP vs BPC WT), 2018 | IMpower-130 (WT), 2019 | IMpower-132 (WT), 0 | IMpower-131 (ACnP), 2020 | IMpower-131 (ACP) EXPLORATORY, 2020 | ||
| atezolizumab alone | 3 | T1 | T1 | T1 | |||||||||
| atezolizumab plus carboplatin plus nab-paclitaxel | 3 | T1T0 | T1 | T1 | |||||||||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 3 | T1 | T1 | T1 | |||||||||
| atezolizumab plus carboplatin plus paclitaxel | 2 | T1 | T1 | ||||||||||
| atezolizumab plus pemetrexed and platin | 1 | T1 | |||||||||||
| pemetrexed plus platin | 0 | T0 | |||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | |||||||||
| nab-paclitaxel | 0 | T0 | |||||||||||
| carboplatin plus nab-paclitaxel | 0 | T0 | T0 | ||||||||||
| bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 | T0 | T0 | ||||||||